期刊文献+

醋酸烯诺孕酮透皮贴剂的制备及不同促渗剂对其促渗作用考察 被引量:6

Preparation of Nestorone Transdermal Patches and Study on the Effect of Different Permeation Enhancer on It
原文传递
导出
摘要 目的:制备醋酸烯诺孕酮透皮贴剂,并考察5种促渗剂单用和联用对贴剂的促渗作用。方法:采用正交试验,以初黏力和累积渗透量(Q)为指标,优化Druo-tak87-2287压敏胶、聚维酮(PVP)K30、乙酰丙酮铝的用量,考察250h内的平均Q;比较质量分数均为5%的氮酮(Azone)、油酸(OA)、肉豆蔻酸异丙酯(IPM)、桉叶油(OE)和丙二醇(PG)及1%、3%、5%、7%OE和3%OE+1%Azone、3%OE+3%Azone、3%OE+5%Azone的贴剂250h内的Q、透皮速率常数(Jss)及增渗倍数。结果:压敏胶、PVPK30、乙酰丙酮铝的用量分别为15、2、0.03g,250h的平均Q为60.83μg/cm2;5%OE单用时250h内的Q最大,为118.12μg/cm2,Jss为0.71μg/(cm2·h),增渗倍数为2.2;3%OE+5%Azone联用时250h内的Q最大,为175.96μg/cm2,Jss为1.102μg(/cm2·h),增渗倍数为3.22。结论:所制备的贴剂初黏力符合要求,3%OE+5%Azone对醋酸烯诺孕酮透皮贴剂有明显促渗作用。 OBJECTIVE: To prepare Nestorone transdermal patches, and to investigate the effect of 5 kinds of enhancing permeation by enhancers used alone or combined. METHODS: Druo-tak 87-2287 PSA, PVP K 30, amount of aluminum acetylacetonate and 250 h average cumulative permeation quantity (Q) were optimized with orthogonal design using Q and the initial adhesive force as index. Q within 250 h, percutaneous rate constant (Jss) and enhancing rate were compared among 5% Azone, 5% OA, 5% IPM, 5% OE and 5% PG, 1% OE, 3% OE, 5% OE and 7% OE, 3% OE+1% Azone, 3% OE+3% Azone, 3% OE+5% Azone. RESULTS: The amounts ofPSA, PVP K 30 and aluminum acetylacetonate were 15 g, 2 g and 0.03 g, and average Q within 250 h was 60.83 μg/cm2; the maximum Q within 250 h of 5% OE used alone was 118.12 μg/cm2, and Jss and enhancing rate were 0.71 μg/(cm2.h) and 2.2; the maximum Q within 250 h of 3% OE+5% Azone was 175.96 μg/cm^2, and Jss and enhancing rate were 1.102 μg/(cm2. h) and 3.22. CONCLUSIONS: The initial adhesive force of prepared patches is in line with the requirement, and 3 % OE+5 % Azone promote the permeation of Nestorone transdermal patches significantly.
出处 《中国药房》 CAS CSCD 2013年第17期1587-1590,共4页 China Pharmacy
关键词 醋酸烯诺孕酮 透皮贴剂 制备 正交试验 促渗剂 促渗作用 Nestorone Transdermal patches Preparation Orthogonal experiment Enhancer Effect of enhancing permeation
  • 相关文献

参考文献11

  • 1黄勇,曹霖,顾芝萍.避孕药物醋酸烯诺孕酮的研究进展[J].生殖与避孕,2003,23(3):169-175. 被引量:2
  • 2NoéG,Salvatierra A,Heikinheimo O,et al.Parmacoki-netics and bioavail-ability of ST-1435administered by dif-ferent routes[J].Contraception,1993,48(6):548.
  • 3Countinho EM,Da Silva AR,Kraft HG.Fertility control with sub-dermal silastic capsules containing a new proges-tin:ST-1435[J].Int J Fertil,1976(2):103.
  • 4L hteenm ki PL.Intestinal absorption of ST-1435in rats[J].Contraception,1984,30(2):143.
  • 5Kumar N,Doide SS,Tsong Y,et al.Nestrone(R):a pro-gestin with a unique pharmacological profile[J].Steroids,2000,65(10/11):629.
  • 6L hteenm ki PL,Hammond GL,Luukkainen T.Serum non-protein bound percentage and distribution of the pro-gestin ST-1435:no effect of ST-1435treatment on plas-ma SHBG and CBG binding capacities[J].Acta Endocri-nol:Copenh,1983,102(2):307.
  • 7Haukkamaa M,Laurikka-Routti M,Heikinheimo O.Tra-nsdermal absorption of the progestin ST-1435:therapeu-tic serum steroid concentrations and high excretion of the steroid in saliva[J].Contraception,1991,44(3):269.
  • 8Suhonen S,Haukkamaa M,L hteenm ki P,et al.Endome-trial effect of transdermal estradiol and progestin ST-1435in postmenopausal women[J].Fertil Steril,1992,57(6):1211.
  • 9任重远,钱忠直,王平.贴膏剂(贴剂)的粘着力及其测定方法[J].药物分析杂志,2008,28(1):159-162. 被引量:10
  • 10费艳,许建辰.促渗剂对苯妥英钠体外经皮渗透的影响[J].中国药房,2008,19(10):747-749. 被引量:3

二级参考文献81

共引文献35

同被引文献120

  • 1杨惊,沈一丁.三聚氰胺甲醛树脂及其衍生物的研究现状与应用前景[J].化工时刊,2004,18(12):12-15. 被引量:49
  • 2朱焰,孙祖越,曹霖.第四代孕激素研究进展[J].中国药学杂志,2006,41(8):572-576. 被引量:16
  • 3张克建.中国桉叶油的开发与利用[J].林业科技开发,1997,11(4):20-21. 被引量:6
  • 4SITRUK-WARE R. New progestogens: a review of their effects inperimenopausal and postmenopausal women [ J ] . Drugs Aging,2004,21(13) :865 -883.
  • 5SITRUK-WARE R. Delivery options for contraceptives[ J]. DrugDiscov Today, 2005,10(14) :977 -985.
  • 6KUMAR N,KOIDE SS,TSONG YY,et al- Nestorone? : a proges-tin v/ith a unique pharmacological profile [ J ]. Steroids ,2000 ,65?10-11) :629 -636.
  • 7SITRUK-WARA R,NATH A,MISHELL DR Jr. Contraceptiontechnology : past, present and future [ J ]. Contraception, 2013 , B7(3):319 -330.
  • 8COUTINHO EM,ATHAYDE C,DANTAS C,et al. Use of a singleimplant of elcometrine ( ST-1435 ),a nonorally active progestin,as a long acting contraceptive for postpartum nursing women [ J ].Contraception, 1999 ,59(2) :115 - 122.
  • 9MASSAI MR, DIAZ S, QUINTEROS E, et al. Contraceptive ef-ficacy and clinical performance of Nestorone implants in postpar-tum women[ J]. Contraception, 2001,64 (6) :369 - 376.
  • 10DIAZ S, SCHIAPPACASSE V, PAVEZ M, et al. Clinical trialwith Nestorone? subdermal contraceptive implants [ J ] . Contra-ception ,\995 ,51 (\) :33 -38.

引证文献6

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部